期刊文献+
共找到485篇文章
< 1 2 25 >
每页显示 20 50 100
Efficacy of Bee Products(Anzer Honey,Pollen and Propolis)in Detection and Healing of Damage Induced by Antidiabetic Drug Vildagliptin/Metformin Hydrochloride in Healthy Human Pancreatic Cells:Cytotoxic,Genotoxic and Biochemical Studies
1
作者 ÖzlemÖzdemir ZinetÇöl Ömer Ertürk 《Current Medical Science》 SCIE CAS 2023年第6期1173-1182,共10页
Background and Objective Although drugs are powerful therapeutic agents,they have a range of side effects.These side effects are sometimes cellular and not clinically noticeable.Vildagliptin/metformin hydrochloride is... Background and Objective Although drugs are powerful therapeutic agents,they have a range of side effects.These side effects are sometimes cellular and not clinically noticeable.Vildagliptin/metformin hydrochloride is one of the most widely used oral antidiabetic drugs with two active ingredients.In this study,we investigated its harmful effects on the metabolic activation system in healthy human pancreatic cells“hTERT-HPNE”,and we aimed to improve these harmful effects by natural products.To benefit from the healing effect,we used the unique natural products produced by the bees of the Anzer Plateau in the Eastern Black Sea Region of Turkey.Methods Cytotoxic and genotoxic effects of the drug were investigated by different tests,such as MTT,flow cytometry-apoptosis and comet assays.Anzer honey,pollen and propolis were analyzed by gas chromatography/mass spectrometry(G/C-MS).A total of 19 compounds were detected,constituting 99.9%of the samples.Results The decrease in cell viability at all drug concentrations was statistically significant compared to the negative control(P<0.05).A statistically significant decrease was detected in the apoptosis caused by vildagliptin/metformin hydrochloride with the supplementation of Anzer honey,pollen and propolis in hTERT-HPNE cells(P<0.05).Conclusion This study can contribute to other studies testing the healing properties of natural products against the side effects of oral antidiabetics in human cells.In particular,Anzer honey,pollen and propolis can be used as additional foods to maintain cell viability and improve heal damage and can be evaluated against side effects in other drug studies. 展开更多
关键词 cell viability hTERT-HPNE Anzer bee products drug side effect diabetes mellitus
下载PDF
Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T 被引量:5
2
作者 Li-Bo YU Xin-Shu Dong +2 位作者 Wen-Zhou sun Dong-Lu Zhao Yue Yang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第40期6385-6388,共4页
AIML To investigate the effect and mechanism of action of the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME) on invasion and metastasis of human colorectal cancer cell line SL-174T... AIML To investigate the effect and mechanism of action of the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME) on invasion and metastasis of human colorectal cancer cell line SL-174T. METHODS: Human colorectal cancer cel4 line SL-174T was cultured and treated separately with four different dosages of L-NAME for 72 h, Nitric oxide (NO) production was measured with Griess reagent, The effect of L-NAME on invasion and migration of SL-174T cells were evaluated by using Transwell chambers attached with polycarbonate filters and reconstituted basement membrane (Matrigel), RT-PCR was performed to determine the mRNA levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor metalloproteinase-2 (TIMP-2),RESULTS: L-NAME could significantly inhibit NO production of SL-174T in a dose-dependent manner. After being treated for 72 h with 0.2, 0.4, 0.8, and 1.0 mmol/L L- NAME, respectively, the ability of the L-NAME treated SL- 174T cells to invade the reconstituted basement membrane decreased significantly (t = 8.056, P〈0.05; t= 14.467, P〈0.01; t= 27.785, P〈0.01; and t= 29.405, P〈0.01, respectively) and the inhibition rates were 10.29%, 19.62%, 34.08%, and 42.23%, respectively. Moreover, L-NAME could inhibit migration of SL-174T cells, and the inhibition rates were 20.76%, 24.95%, 39.43%, and 46. 85% for L-NAME at 0.2, 0.4, 0.8, and 1.0 mmol/L, respectively (t = 15.116, P〈0.01). In addition, after treatment with L-NAME, expression of MMP-2 mRNA was significantly decreased (t = 71.238, P〈0.01) and that of TIMP-2 mRNA was markedly increased (t = -13.020, P〈0.01). CONCLUSION: L-NAME exerts anti-invasive and anti- metastatic effects on SL-174T cell line via downregulating MNP-2 mRNA expression and upregulating TIMP-2 mRNA expression. 展开更多
关键词 Colorectal Neoplasms Neoplasm Invasiveness cell Line Tumor cell movement Dose-Response Relationship drug FEMALE Gelatinase A Humans Male NG-Nitroarginine Methyl Ester Nitric Oxide Nitric Oxide Synthase INHIBITORS Tissue Inhibitor of Metalloproteinase-2
下载PDF
Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma 被引量:50
3
作者 Wei Wang~1 Shu-Kui Qin~1 Bao-An Chen~2 Hui-Ying Chen~1 1 Chinese PLA Cancer Center,Chinese PLA 81 Hospital,Nanjing 210002,Jiangshu Province,China2 Affliliated Zhongda Hospital of Southeast University Medical College,Nanjing 210087,Jiangsu Province,China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第5期702-705,共4页
INTRODUCTIONThe main component of a traditional Chinese drug 'Pishuang'. arsenic trioxide (As2O3), has obviously selective anti-tumor effect on human hepatocellular carcinoma (HCC)in both in vitro and in vivo ... INTRODUCTIONThe main component of a traditional Chinese drug 'Pishuang'. arsenic trioxide (As2O3), has obviously selective anti-tumor effect on human hepatocellular carcinoma (HCC)in both in vitro and in vivo studies[1-5]. Due to limited effectiveness when any anti-carcinogen is used alone and obviously increased toxicity when the dose is raised, there is no exception for As2O3. Furthermore, combined chemotherapy contributes to improve therapeutic effectiveness, disperse toxicity and surmount drug-resistance,in which the combination of traditional Chinese and modern medicine has more advantages and characteristics. As a result,we made an experimental study on anti-tumor effect of As2O3in combination with cisplantin (PDD) or doxorubicin (ADM)on HCC. to investigate the possibility of AS2O3 in combination with PDD or ADM and nature of interaction between them,and to provide experimental basis for clinical application. 展开更多
关键词 Animals Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols ARSENICALS Carcinoma Hepatocellular CISPLATIN DOXORUBICIN Female Humans Liver Neoplasms Experimental Male MICE Mice Inbred Strains Neoplasm Transplantation Oxides Research Support Non-U.S. Gov't Tumor cells Cultured
下载PDF
Effects of aminoguanidine on nitric oxide production induced by inflammatory cytokines and endotoxin in cultured rat hepatocytes 被引量:20
4
作者 Guo Liang Zhang Ye Hong Wang Hui Ling Teng Zhi Bin Lin Department of Pharmacology,School of Basic Medical Sciences,Beijing University,Beijiog 100083,ChinaDr.Guo Liang Zhang graduated from Xinxiang Medical College in 1982,got Ph.D.at Nagoya City University Medical School,Japan in 1994,finished postdoctoral research at Beijing Medical Univcrsity in 1996,now an associate professor of pharmacology,specialized in hepatic pharmacology,having 15 papers published. 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第3期331-334,共4页
AIM: To study the effects of aminoguanidine (AG) and two L-arginine analogues N(omega)-nitro-L-arginine methyl ester (L-NAME) and N(omega)-nitro-L-arginine (L-NNA) on nitric oxide (NO) production induced by cytokines ... AIM: To study the effects of aminoguanidine (AG) and two L-arginine analogues N(omega)-nitro-L-arginine methyl ester (L-NAME) and N(omega)-nitro-L-arginine (L-NNA) on nitric oxide (NO) production induced by cytokines (TNF-alpha, IL-1 beta, and IFN-gamma) and bacterial lipopolysaccharide (LPS) mixture (CM) in the cultured rat hepatocytes, and examine their mechanisms action. METHODS: Rat hepatocytes were incubated with AG, L-NAME, L-NNA, Actinomycin D (ActD) and dexamethasone in a medium containing CM (LPS plus TNF-alpha, IL-1 beta, and IFN-gamma) for 24h. NO production in the cultured supernatant was measured with the Griess reaction. Intracellular cGMP level was detected with radioimmunoassy. RESULTS: NO production was markedly blocked by AG and L-NAME in a dose-dependent manner under inflammatory stimuli condition triggered by CM in vitro. The rate of the maximum inhibitory effects of L-NAME (38.9%) was less potent than that obtained with AG(53.7%, P 【 0.05). There was no significant difference between the inhibitory effects of AG and two L-arginine analogues on intracellular cGMP accumulation in rat cultured hepatocytes. Non-specific NOS expression inhibitor dexamethasone (DEX)and iNOS mRNA transcriptional inhibitor ActD also significantly inhibited CM-induced NO production. AG(0.1 mmol x L(-1)) and ActD (0.2 ng x L(-1)) were equipotent in decreasing NO production induced by inflammatory stimuli in vitro, and both effects were more potent than that induced by non-selectivity NOS activity inhibitor L-NAME (0.1 mmol x L(-1)) under similar stimuli conditions (P【0.01). CONCLUSION: AG is a potent selective inhibitor of inducible isoform of NOS,and the mechanism of action may be not only competitive inhibition in the substrate level, but also the gene expression level in rat hepatocytes. 展开更多
关键词 Animals Antineoplastic Agents cells Cultured Comparative Study Cyclic GMP Cytokines DACTINOMYCIN Dexamethasone Enzyme Inhibitors Glucocorticoids GUANIDINES Hepatocytes Interferon Type II INTERLEUKIN-1 LIPOPOLYSACCHARIDES Male NG-Nitroarginine Methyl Ester Nitric Oxide Nitric Oxide Synthase inhibitors Nitroarginine Protein Synthesis Inhibitors RATS Rats Wistar Research Support Non-U.S. Gov't Tumor Necrosis Factor-alpha
下载PDF
奥希替尼在老年非小细胞肺癌患者靶向治疗中的应用效果及对T细胞水平的影响 被引量:1
5
作者 吴俊沛 方权 +1 位作者 朱晓丹 吴洪 《中国药物与临床》 CAS 2024年第8期491-496,共6页
目的 探讨奥西替尼在老年非小细胞肺癌患者靶向治疗中的效果及对免疫水平的影响。方法 回顾性选择2018年1月至2020年12月老年非小细胞肺癌患者116例研究,根据治疗方法不同分为2组,各58例。对照组采用常规放化疗治疗,观察组在对照组基础... 目的 探讨奥西替尼在老年非小细胞肺癌患者靶向治疗中的效果及对免疫水平的影响。方法 回顾性选择2018年1月至2020年12月老年非小细胞肺癌患者116例研究,根据治疗方法不同分为2组,各58例。对照组采用常规放化疗治疗,观察组在对照组基础上联合奥西替尼治疗,3个月治疗后评估患者效果,比较2组总有效率、T细胞水平(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物水平、不良反应发生率。结果 观察组治疗3个月总有效率为44.8%高于对照组25.9%(P<0.05);2组治疗后3个月CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前(P<0.05);CD8^(+)水平高于治疗前(P<0.05);观察组治疗后3个月CD3^(+)(58.95±4.21)%、CD4^(+)(32.59±3.11)%、CD4^(+)/CD8^(+)(1.21±0.22)高于对照组(P<0.05);CD8^(+)(26.81±3.32)%低于对照组(P<0.05);观察组干预3个月后CA125(91±8)U/ml、CYFRA21-1(1.26±0.24)μg/L及癌胚抗原(CEA)水平(34±5)μg/L均低于对照组(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论 奥西替尼用于老年非小细胞肺癌患者靶向治疗中,能获得较好的总有效率,对患者T细胞水平影响较小,可降低肿瘤标志物水平,未增加不良反应发生率,值得临床推广应用。 展开更多
关键词 非小细胞肺 分子靶向治疗 T淋巴细胞 生物标记 肿瘤 药物相关性副作用和不良反应 奥西替尼
下载PDF
替雷利珠联合化疗治疗非小细胞肺癌手术患者的效果 被引量:1
6
作者 高薇薇 邵春艳 +2 位作者 姜洁 王欢 张磊 《中国药物应用与监测》 CAS 2024年第2期106-109,共4页
目的评价替雷利珠单抗在含铂双药化疗治疗的非小细胞肺癌手术患者中的应用效果。方法选取2022年1月—2023年12月收治的100例拟行手术治疗的非小细胞肺癌患者,根据随机数字表法将其分成两组。对照组50例患者在术前给予含铂双药治疗,观察... 目的评价替雷利珠单抗在含铂双药化疗治疗的非小细胞肺癌手术患者中的应用效果。方法选取2022年1月—2023年12月收治的100例拟行手术治疗的非小细胞肺癌患者,根据随机数字表法将其分成两组。对照组50例患者在术前给予含铂双药治疗,观察组50例患者在其治疗基础上加用替雷利珠单抗治疗。比较两组临床疗效、无事件及无疾病生存率、生活质量改善情况、不良反应。结果观察组临床疗效(完全缓解率:20.00%vs.10.00%)及病理评估(主要病理学缓解率:46.00%vs.20.00%)优于对照组(Z=3.484,P<0.001;χ^(2)=7.664,P=0.006);Kaplan-Meier生存分析显示,观察组无事件生存率(84.00%vs.60.00%)及无疾病生存率(78.00%vs.60.00%)均高于对照组(χ^(2)=4.298,P=0.038;χ^(2)=4.783,P=0.029);在生活质量改善率方面,观察组(64.00%)较对照组高(42.00%),差异有统计学意义(χ^(2)=4.857,P=0.028);两组不良反应发生率(18.00%vs.22.00%)比较,差异无统计学意义(χ^(2)=0.250,P=0.617)。结论在含铂双药化疗治疗非小细胞肺癌手术患者中的实施替雷利珠单抗治疗可提高治疗效果,促进生活质量改善,且不会增加不良反应发生风险。 展开更多
关键词 非小细胞肺癌 替雷利珠单抗 含铂双药 临床疗效 不良反应
下载PDF
养肺益气汤联合载药微球支气管动脉化疗在非小细胞肺癌治疗中的临床效果分析
7
作者 陆凯娟 徐佳丽 +1 位作者 张娟 陈红英 《中外医学研究》 2024年第6期18-21,共4页
目的:分析养肺益气汤联合载药微球支气管动脉化疗治疗非小细胞肺癌的临床效果。方法:选择2020年1月—2023年1月启东市中医院肿瘤科收治的82例非小细胞肺癌患者,根据随机数表法分为化疗组、联用组,各41例。其中化疗组采用载药微球支气管... 目的:分析养肺益气汤联合载药微球支气管动脉化疗治疗非小细胞肺癌的临床效果。方法:选择2020年1月—2023年1月启东市中医院肿瘤科收治的82例非小细胞肺癌患者,根据随机数表法分为化疗组、联用组,各41例。其中化疗组采用载药微球支气管动脉化疗治疗,而联用组采用养肺益气汤联合载药微球支气管动脉化疗治疗。比较两组肿瘤标志物、中医症候积分、毒副作用发生率。结果:治疗前,两组肿瘤标志物比较,差异无统计学意义(P>0.05);治疗后,两组肿瘤标志物均低于治疗前,且联用组低于化疗组,差异有统计学意义(P<0.05)。治疗前,两组中医症候积分比较,差异无统计学意义(P>0.05);治疗后,两组中医症候积分均低于治疗前,且联用组低于化疗组,差异有统计学意义(P<0.05)。联用组毒副作用总发生率低于化疗组,差异有统计学意义(P<0.05)。结论:在针对非小细胞肺癌进行治疗时,在载药微球支气管动脉化疗基础上予以养肺益气汤治疗能够进一步控制癌症病变,缓解各项临床症状,并降低毒副作用发生的可能性。 展开更多
关键词 养肺益气汤 载药微球支气管动脉化疗 非小细胞肺癌 肿瘤标志物 毒副作用
下载PDF
阿替利珠单抗不良反应94例文献分析
8
作者 余萌 周红 +2 位作者 承华薇 许荣蓉 孙言才 《安徽医药》 CAS 2024年第1期205-212,共8页
目的分析阿替利珠单抗发生不良反应(adverse reactions,ADRs)的临床特点与规律,为临床安全用药提供参考。方法搜索中国知网、维普、万方、Web of Science、PubMed数据库,收集关于阿替利珠单抗所致不良反应的报道文献并进行分析,研究时间... 目的分析阿替利珠单抗发生不良反应(adverse reactions,ADRs)的临床特点与规律,为临床安全用药提供参考。方法搜索中国知网、维普、万方、Web of Science、PubMed数据库,收集关于阿替利珠单抗所致不良反应的报道文献并进行分析,研究时间为2022年4—8月。结果阿替利珠致不良反应报道共94例;其中男性56例(59.57%),女性38例(40.43%),男性占比较高;年龄(62.8±12.0)岁,中老年人居多;多数发生在用药后的90 d内(71例,71.0%);阿替利珠单抗致ADRs累及多个系统/器官,其中以神经系统损害(22例,22.0%)占比最多;3~4级严重ADRs占比最多(64例,64.0%);94例经治疗和(或)停药后,好转或治愈80例,死亡5例。结论阿替利珠单抗所致ADRs涉及不同性别与年龄段病人,累及多个系统/器官,临床使用应随时监测,警惕ADRs的发生,做到及时识别与治疗。 展开更多
关键词 阿替利珠单抗 药物相关性副作用和不良反应 抗体 单克隆 程序性细胞死亡受体1
下载PDF
PD-1抑制剂联合抗血管生成药物治疗晚期NSCLC的疗效及安全性分析
9
作者 魏小寒 王国祥 《四川医学》 CAS 2024年第6期607-612,共6页
目的探讨程序性死亡蛋白-1(PD-1)抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法选取我院2019年1月至2021年11月收治的137例晚期NSCLC患者作为研究对象,按治疗方法分为两组。PD-1抑制剂联合抗血管生成药物... 目的探讨程序性死亡蛋白-1(PD-1)抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法选取我院2019年1月至2021年11月收治的137例晚期NSCLC患者作为研究对象,按治疗方法分为两组。PD-1抑制剂联合抗血管生成药物治疗者81例(联合组),PD-1抑制剂单药治疗者56例(单药组)。统计分析两组客观缓解率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)、总生存时间(OS)、血管内皮生长因子(VEGF)、肿瘤体积(TV)、预后生存曲线及毒副反应相关数据。结果联合组ORR和DCR显著高于单药组,差异有统计学意义(χ^(2)=4.219,3.583;P=0.040,0.045);联合组PFS和OS均显著长于单药组,差异有统计学意义(Z=7.017,5.778;P<0.001);两组治疗后VEGF和TV水平均明显下降(P<0.001),且治疗1、2个周期后联合组VEGF和TV水平均显著低于单药组,差异有统计学意义(P<0.001);两组Kaplan-Meier预后生存曲线比较差异有统计学意义(χ^(2)_(L)=5.338,P=0.027);两组患者恶心呕吐、头疼、疲劳、腹泻、皮疹、贫血、便秘、呼吸困难及关节痛发生率和Ⅲ级以上毒副反应发生率比较,差异无统计学意义(P>0.05)。结论PD-1抑制剂联合抗血管生成药物可抑制肿瘤微血管增生,缩小TV,提高ORR和DCR,延长PFS和OS,Ⅲ级以上毒副反应发生率低,毒副反应总体安全可控,有助于增加晚期NSCLC患者获益。 展开更多
关键词 非小细胞肺癌 晚期 程序性死亡蛋白-1 抗血管生成药物 安全性 疗效
下载PDF
归脾汤加减联合免疫化学药物治疗气血亏虚型非小细胞肺癌疗效观察
10
作者 廖明 谢志明 +3 位作者 邓娟华 谢魁 刘彬 邹国明 《江西中医药大学学报》 2024年第5期39-42,46,共5页
目的:研究分析归脾汤加减联合免疫化学药物治疗气血亏虚型非小细胞肺癌(NSCLC)疗效。方法:选取2021年1月—2023年12月井冈山大学附属医院和峡江县人民医院收治的60例中医辨证为气血亏虚型的非小细胞肺癌患者作为本次研究对象,根据不同... 目的:研究分析归脾汤加减联合免疫化学药物治疗气血亏虚型非小细胞肺癌(NSCLC)疗效。方法:选取2021年1月—2023年12月井冈山大学附属医院和峡江县人民医院收治的60例中医辨证为气血亏虚型的非小细胞肺癌患者作为本次研究对象,根据不同治疗方案进行分组,即对照组与观察组,各30例。2组患者均接受免疫化学药物、护胃、营养支持、镇痛等常规对症治疗。对照组实施免疫化学药物治疗,采用含替雷利珠单抗免疫化学药物治疗方案,治疗3个疗程,至疾病进展,或有不耐受毒性。观察组采用归脾汤加减联合免疫化学药物,治疗3个疗程。比较2组患者临床治疗效果、气血亏虚型中医证候积分、功能状态评分、生存质量评分及不良反应发生情况差异。结果:经不同用药方案治疗后,观察组临床治疗总有效率高于对照(P<0.05);观察组气血亏虚型中医证候积分低于对照组(P<0.05);观察组生活质量评分各条目得分均优于对照组(P<0.05);观察组肿瘤病人功能状态评分低于对照组(P<0.05);与对照组相比,观察组患者的周围神经损伤、免疫性肺炎、骨髓抑制、胃肠道反应及肝肾功能异常等不良反应发生率显著降低,差异具有统计学意义(P<0.05)。结论:采用归脾汤加减联合免疫化学药物治疗气血亏虚型非小细胞肺癌疗效显著,不仅能够有效缓解患者气血亏虚的症状,还能够降低西医治疗过程中的不良反应发生率,显著提升患者的生活质量。 展开更多
关键词 归脾汤加减 免疫化学药物 气血亏虚型 非小细胞肺癌 疗效观察
下载PDF
屎肠球菌Ef026的体外益生特性研究
11
作者 汤伟 李佳欣 +3 位作者 唐涛 孙晓雯 乔晓妮 何增国 《中国饲料》 北大核心 2024年第19期39-46,共8页
本试验旨在探究屎肠球菌Ef026的体外益生特性,挖掘其开发成饲用微生物制剂的潜力。通过对菌株的耐受性、细胞表面特性、抑菌作用、抗氧化作用及药敏试验,全面评价了其体外益生特性。结果显示:屎肠球菌Ef026在pH 3.0及0.3%的胆盐浓度下... 本试验旨在探究屎肠球菌Ef026的体外益生特性,挖掘其开发成饲用微生物制剂的潜力。通过对菌株的耐受性、细胞表面特性、抑菌作用、抗氧化作用及药敏试验,全面评价了其体外益生特性。结果显示:屎肠球菌Ef026在pH 3.0及0.3%的胆盐浓度下具有良好的耐受性;能够耐受70℃高温;具有极高的黏附性,其黏附指数为(38.00±1.67)%;对多种畜禽和水产养殖中常见病原菌具有一定的抑制作用;菌株完整细胞能够耐受2.0 mM H_(2)O_(2),同时还具有还原能力、DPPH·清除力、·O_(2)^(-)清除力和抗脂质过氧化能力;对常用抗生素具有不同程度的敏感性。屎肠球菌Ef026具有优良的体外益生特性,具有开发成饲用微生物制剂的价值。 展开更多
关键词 屎肠球菌 耐受性 细胞表面特性 抑菌作用 抗氧化作用 药敏试验
下载PDF
基于RTCA技术研究抗体偶联药物的旁观者效应的检测方法
12
作者 曹天助 牛庆田 +3 位作者 刘兵 昌根琼 林军 罗顺 《中南药学》 CAS 2024年第5期1227-1231,共5页
目的 利用实时无标记细胞分析(RTCA)系统评估抗体偶联药物(ADC)的旁观者效应。方法 采用RTCA系统监测抗原阳性细胞(Ag^(+))和抗原阴性细胞(Ag^(-))的共培养状态,观察Ag^(-)的细胞存活情况;采用重复实验验证结果的可靠性和一致性,并采用... 目的 利用实时无标记细胞分析(RTCA)系统评估抗体偶联药物(ADC)的旁观者效应。方法 采用RTCA系统监测抗原阳性细胞(Ag^(+))和抗原阴性细胞(Ag^(-))的共培养状态,观察Ag^(-)的细胞存活情况;采用重复实验验证结果的可靠性和一致性,并采用单因素方差分析比较不同细胞比例培养组在单个时间点的Ag^(-)存活率。结果 加入抗体偶联药物后,随着共培养时间的延长,Ag^(-)存活率下降;此外,在单个时间点(96 h)上,与0%Ag^(+)细胞的Ag^(-)细胞存活率相比,10%Ag^(+)细胞的Ag^(-)细胞存活率为89.07%(P=0.156),25%Ag^(+)细胞的Ag^(-)存活率为68.93%(P=0.0026),50%Ag^(+)、75%Ag^(+)和90%Ag^(+)细胞的Ag^(-)存活率分别为35.28%、13.99%和12.02%(P<0.0001)。在 Ag^(+)细胞比例为25%~90%时,旁杀伤效果显著;重复性结果显示不同Ag^(+)细胞的旁杀伤率的相对标准偏差(RSD)均小于30%。结论 结合RTCA技术和共培养方式的方法,可以更准确地模拟旁观者效应的生物学过程,为后续的抗体偶联药物开发提供有价值的参考。 展开更多
关键词 抗体偶联药物 实时无标记细胞分析 旁观者效应 细胞存活 旁杀伤率
下载PDF
阿美替尼、吉非替尼治疗EGFR突变局部晚期非小细胞肺癌的效果及预后
13
作者 曾含梅 王利民 《临床误诊误治》 CAS 2024年第10期39-43,共5页
目的探讨阿美替尼、吉非替尼治疗表皮生长因子受体(EGFR)突变局部晚期非小细胞肺癌(NSCLC)的效果及预后。方法选取2019年3月至2022年9月确诊的100例EGFR突变局部晚期NSCLC,根据治疗方式不同分为A组(n=57)和B组(n=43),A组采用阿美替尼治... 目的探讨阿美替尼、吉非替尼治疗表皮生长因子受体(EGFR)突变局部晚期非小细胞肺癌(NSCLC)的效果及预后。方法选取2019年3月至2022年9月确诊的100例EGFR突变局部晚期NSCLC,根据治疗方式不同分为A组(n=57)和B组(n=43),A组采用阿美替尼治疗,B组采用吉非替尼治疗,均持续治疗2个周期。比较2组的客观缓解率(ORR)和疾病控制率(DCR)、治疗前后血清EGFR水平和免疫球蛋白指标[免疫球蛋白M(IgM)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)]、毒副反应发生率,所有患者随访12~42个月,绘制生存曲线,比较2组中位总生存期(OS)和中位无进展生存期(PFS)。结果A组ORR和DCR分别为28.07%和77.19%,B组分别为11.63%和44.19%,差异均有统计学意义(P<0.05)。治疗后,A组血清EGFR水平较B组低,IgM、IgA和IgG水平较B组高,差异有统计学意义(P<0.05)。A组<3级毒副反应发生率为71.93%,≥3级毒副反应发生率为21.05%,B组<3级毒副反应发生率为48.84%,≥3级毒副反应发生率为41.86%,差异有统计学意义(P<0.05)。A组中位OS和中位PFS分别为16.9个月和5.8个月,B组中位OS和中位PFS分别为10.5个月和4.0个月,差异有统计学意义(P<0.05)。结论与吉非替尼比较,阿美替尼治疗EGFR突变局部晚期NSCLC患者效果更好,可以更好控制病情发展,改善EGFR水平和免疫指标,提高患者生存率,且具有一定的安全性。 展开更多
关键词 非小细胞肺癌 阿美替尼 吉非替尼 表皮生长因子受体 免疫球蛋白A 治疗效果 药物毒性 无进展生存时间
下载PDF
Personalized targeted therapy for esophageal squamous cell carcinoma 被引量:13
14
作者 Xiaozheng Kang Keneng Chen +3 位作者 Yicheng Li Jianying Li Thomas A D'Amico Xiaoxin Chen 《World Journal of Gastroenterology》 SCIE CAS 2015年第25期7648-7658,共11页
Esophageal squamous cell carcinoma continues to heavily burden clinicians worldwide. Researchers have discovered the genomic landscape of esophageal squamous cell carcinoma, which holds promise for an era of personali... Esophageal squamous cell carcinoma continues to heavily burden clinicians worldwide. Researchers have discovered the genomic landscape of esophageal squamous cell carcinoma, which holds promise for an era of personalized oncology care. One of the most pressing problems facing this issue is to improve the understanding of the newly available genomic data, and identify the driver-gene mutations, pathways, and networks. The emergence of a legion of novel targeted agents has generated much hope and hype regarding more potent treatment regimens, but the accuracy of drug selection is still arguable. Other problems, such as cancer heterogeneity, drug resistance, exceptional responders, and side effects, have to be surmounted. Evolving topics in personalized oncology, such as interpretation of genomics data, issues in targeted therapy, research approaches for targeted therapy, and future perspectives, will be discussed in this editorial. 展开更多
关键词 Cancer heterogeneity Cultured tumorcells Driver mutation drug side effects Esophagealsquamous cell carcinoma Exceptional RESPONDER Highthroughputnucleotide sequencing NEOPLASM drugRESISTANCE PERSONALIZED medicine XENOGRAFT model
下载PDF
Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice 被引量:21
15
作者 Xing Wang Wang~1 Jin Hui Yuan~1 Ru Gang Zhang~1 Li Xia Guo~1 Yong Xie~2 Hong Xie~1 ~1Department of Biotherapy,Shanghai Institute of Cell Biology,Chinese Academy of Sciences,Shanghai 200031,China ~2Department of Biology,Hong Kong University of Science and Technology,ChinaDr.Xing Wang Wang earned Ph.D.from Shanghai Institute of Materia Medical,Chinese Academy of Sciences in 1997.Now a professor at Shanghai Institute of Cell Biology,Chinese Academy of Sciences. 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第3期345-351,共7页
AIM: To evaluate antihepatoma effect of antisense phosphorothioate oligodeoxyribonucleotides (S-ODNs) targeted to alpha-fetoprotein (AFP) genes in vitro and in nude mice. METHODS: AFP gene expression was examined by i... AIM: To evaluate antihepatoma effect of antisense phosphorothioate oligodeoxyribonucleotides (S-ODNs) targeted to alpha-fetoprotein (AFP) genes in vitro and in nude mice. METHODS: AFP gene expression was examined by immunocytochemical method or enzyme-linked immunosorbent assay. Effect of S-ODNs on SMMC-7721 human hepatoma cell growth in vitro was determined using microculture tetrazolium assay. In vitro antitumor activities of S-ODNs were monitored by measuring tumor weight differences in treated and control mice bearing SMMC-7721 xenografts. Induction of cell apoptosis was evaluated by fluorescence-activated cell sorter (FACS) analysis. RESULTS: Antisense S-ODN treatment led to reduced AFP gene expression. Specific antisense S-ODNs, but not control S-ODNs, inhibited the growth of hepatoma cells in vitro. In vitro, only antisense S-ODNs exhibited obvious antitumor activities. FACS analysis revealed that the growth inhibition by antisense S-ODNs was associated with their cell apoptosis induction. CONCLUSION: Antisense S-ODNs targeted to AFP genes inhibit the growth of human hepatoma cells and solid hepatoma, which is related to their cell apoptosis induction. 展开更多
关键词 Animals Apoptosis Carcinoma Hepatocellular Gene Expression Gene Therapy Humans In Vitro Liver Neoplasms Male MICE Mice Inbred BALB C Mice Nude Neoplasm Transplantation Oligodeoxyribonucleotides Antisense Research Support Non-U.S. Gov't Transplantation Heterologous Tumor cells Cultured ALPHA-FETOPROTEINS
下载PDF
Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation:Results from a retrospective study on 38 Chinese patients 被引量:1
16
作者 Si-Hua Dang Qin Liu +7 位作者 Rong Xie Na Shen Shu Zhou Wei Shi Wen Liu Ping Zou Yong You Zhao-Dong Zhong 《World Journal of Clinical Cases》 SCIE 2020年第6期1065-1073,共9页
BACKGROUND Graft-vs-host disease (GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation.Some patients have steroid-refractory(SR) GVHD.AIM To evaluate the effect and safety of ru... BACKGROUND Graft-vs-host disease (GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation.Some patients have steroid-refractory(SR) GVHD.AIM To evaluate the effect and safety of ruxolitinib add-on in the treatment of patients with SR acute (a) and chronic (c) GVHD.METHODS We retrospectively analyzed 38 patients administered ruxolitinib add-on to standard immunosuppressive therapy for SR-aGVHD or SR-cGVHD following allogeneic hematopoietic stem cell transplantation.Ruxolitinib was administered5-10 mg/d depending on disease severity,patient status,and the use of antifungal drugs.Overall response rate,time to best response,malignancy relapse rate,infection rate,and treatment-related adverse events were assessed.RESULTS The analysis included 10 patients with SR-aGVHD (gradeⅢ/Ⅳ,n=9) and 28patients with SR-cGVHD (moderate/severe,n=24).For the SR-aGVHD and SRcGVHD groups,respectively:Median number of previous GVHD therapies was 2(range:1-3) and 2 (1-4);median follow-up was 2.5 (1.5-4) and 5 (1.5-10) mo;median time to best response was 1 (0.5-2.5) and 3 (1-9.5) mo;and overall response rate was 100%(complete response:80%) and 82.1%(complete response:10.7%) with a response observed in all GVHD-affected organs.The malignancy relapse rates for the SR-aGVHD and SR-cGVHD groups were 10.0%and 10.7%,respectively.Reactivation rates for cytomegalovirus,Epstein-Barr virus,and varicella-zoster virus,respectively,were 30.0%,10.0%,and 0%for the SR-aGVHD group and 0%,14.3%,and 7.1%for the SR-cGVHD group.CONCLUSION Ruxolitinib add-on was effective and safe as salvage therapy for SR-GVHD. 展开更多
关键词 Graft-vs-host disease Graft-vs-leukemia effect ALLOGENEIC HEMATOPOIETIC stem cell transplantation RUXOLITINIB Treatment ANTIFUNGAL drugs
下载PDF
Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines 被引量:7
17
作者 Edgar Staren Takeshi lwamura +1 位作者 HubertAppert JohnHoward 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第6期855-859,共5页
AIM: To investigate the specific mechanisms of intrinsic and acquired resistance to taxotere (TXT) in pancreatic adenocarcinoma (PAC). METHODS: MTT assay was used to detect the sensitivity of PAC cell line SUIT-2 and ... AIM: To investigate the specific mechanisms of intrinsic and acquired resistance to taxotere (TXT) in pancreatic adenocarcinoma (PAC). METHODS: MTT assay was used to detect the sensitivity of PAC cell line SUIT-2 and its sublines (S-007, S-013, S-020, S-028 and TXT selected SUIT-2 cell line, S2/TXT) to TXT. Mdr1 (P-gp), multidrug resistance associated protein (MRP), lung resistance protein (LRP) and beta-tubulin isotype gene expressions were detected by RT-PCR. The functionality of P-gp and MRP was tested using their specific blocker verapamil (Ver) and indomethacin (IMC), respectively. The transporter activity of P-gp was also confirmed by Rhodamine 123 accumulation assay. RESULTS: S-020 and S2/TXT were found to be significantly resistant to TXT(19 and 9.5-fold to their parental cell line SUIT-2, respectively). RT-PCR demonstrated strong expression of Mdr1 in these two cell lines, but weaker expression or no expression in other cells lines. MRP and LRP expressions were found in most of these cell lines. The TXT-resistance in S2-020 and S2/TXT could be reversed almost completely by Ver, but not by IMC. Flow cytometry showed that Ver increased the accumulation of Rhodamine-123 in these two cell lines. Compared with S-020 and SUIT-2, the levels of beta-tubulin isotype II, III expressions in S-2/TXT were increased remarkably. CONCLUSION: The both intrinsic and acquired TXT-related drug resistance in these PAC cell lines is mainly mediated by P-gp, but had no relationship to MRP and LRP expressions. The increases of beta-tubulin isotype II, III might be collateral changes that occur when the SUIT-2 cells are treated with TXT. 展开更多
关键词 drug Resistance Neoplasm TAXOIDS Antineoplastic Agents Phytogenic Carcinoma Humans Paclitaxel derivatives Pancreatic Neoplasms Research Support Non-U.S. Gov't Tumor cells Cultured
下载PDF
健肝散体外对拉米夫定耐药株病毒表达抑制及增敏作用的研究 被引量:1
18
作者 李堃 葛飞 +4 位作者 孙茂秋 严展鹏 仲婕 季瑜 朱方石 《陕西中医》 CAS 2023年第9期1188-1192,共5页
目的:探讨健肝散(JGP)对HepG2.2.15耐药株对拉米夫定(LMV)耐药的影响。方法:利用药物浓度递增冲击的方法,建立HepG2.2.15/LMV耐药细胞株模型,CCK8法检测耐药株、敏感株IC_(50)值,观察健肝散(JGP)含药血清对耐药株IC_(50)值影响;设置HepG... 目的:探讨健肝散(JGP)对HepG2.2.15耐药株对拉米夫定(LMV)耐药的影响。方法:利用药物浓度递增冲击的方法,建立HepG2.2.15/LMV耐药细胞株模型,CCK8法检测耐药株、敏感株IC_(50)值,观察健肝散(JGP)含药血清对耐药株IC_(50)值影响;设置HepG2.2.15耐药株+正常大鼠血清组及HepG2.2.15耐药株+JGP含药血清组,荧光定量PCR检测两组细胞HBV-pgRNA表达水平,提取RNA后ELISA检测两组细胞上清HBsAg和HBeAg的表达水平。结果:①与HepG2.2.15细胞耐药株+正常大鼠血清组相比,HepG2.2.15细胞耐药株+JGP含药血清的IC_(50)值显著降低;②与耐药细胞株+正常血清组相比,健肝散含药血清可抑制HepG2.2.15 LMV耐药细胞株HBV-pgRNA的表达,差异有统计学意义(P<0.01);③与HepG2.2.15/LMV耐药细胞株添加正常血清组相比,JGP含药血清可抑制HepG2.2.15/LMV耐药细胞株HBsAg和HBeAg的表达,差异具有统计学意义(P<0.01)。结论:JGP体外可以增加耐药株对LMV敏感性,有效降低耐药株HBV的表达,对LMV耐药具有一定缓解作用。 展开更多
关键词 乙肝 健肝散 拉米夫定 耐药 增敏 细胞实验 HEPG2.2.15 抗病毒作用
下载PDF
卡瑞利珠单抗治疗晚期非小细胞肺癌致内分泌系统不良反应临床观察 被引量:3
19
作者 朱方 赵慧慧 +1 位作者 蒋文 朱传东 《安徽医药》 CAS 2023年第9期1904-1908,共5页
目的探讨程序性死亡受体(PD-1)抑制剂卡瑞利珠单抗治疗晚期非小细胞肺癌过程中内分泌系统的免疫相关不良反应(irAEs)的临床情况。方法回顾性分析2019年1月1日至2021年12月31日南京市第二医院收治的共86例接受卡瑞利珠单抗治疗的晚期非... 目的探讨程序性死亡受体(PD-1)抑制剂卡瑞利珠单抗治疗晚期非小细胞肺癌过程中内分泌系统的免疫相关不良反应(irAEs)的临床情况。方法回顾性分析2019年1月1日至2021年12月31日南京市第二医院收治的共86例接受卡瑞利珠单抗治疗的晚期非小细胞肺癌病人,观察治疗期间发生的内分泌系统不良反应,包括甲状腺功能减退症(甲减)、甲状腺功能亢进症(甲亢)、垂体炎、1型糖尿病、甲状旁腺功能亢进症(甲旁亢)或甲状旁腺功能减退症(甲旁减)等。结果86例病人中,17例(19.8%)发生内分泌系统irAEs,其中甲减11例(1~2级10例,3级1例),甲亢2例(1级),甲状腺炎1例(1级),1型糖尿病1例(3级),垂体炎1例(2级),甲旁亢1例(3级),甲旁减0例,未见4级及以上内分泌系统不良反应。发生内分泌系统不良反应的中位时间为首次卡瑞利珠单抗治疗后13.1周。2级及以下irAEs病人经对应治疗后均可以继续接受卡瑞利珠单抗治疗,3级irAEs病人后续根据具体情况可考虑停用卡瑞利珠单抗。结论在使用卡瑞利珠单抗过程中,发生内分泌系统irAEs风险相对较高,其中尤以甲状腺功能障碍发生率较高;但定期监测、及时治疗是安全可控的。 展开更多
关键词 非小细胞肺 药物相关性副作用和不良反应 程序性死亡受体-1 卡瑞利珠单抗 免疫相关不良反应
下载PDF
免疫检查点抑制剂联合抗血管生成药物治疗非小细胞肺癌的疗效和安全性
20
作者 宋佳烨 季进锋 +1 位作者 曹永峰 龚军 《临床和实验医学杂志》 2023年第22期2376-2380,共5页
目的分析免疫检查点抑制剂联合抗血管生成药物治疗非小细胞肺癌的疗效和安全性。方法选择自2020年6月至2021年6月南通市肿瘤医院收治的68例非小细胞肺癌患者作为研究对象,依据随机数字表法分为观察组和对照组,各34例。对照组予以常规化... 目的分析免疫检查点抑制剂联合抗血管生成药物治疗非小细胞肺癌的疗效和安全性。方法选择自2020年6月至2021年6月南通市肿瘤医院收治的68例非小细胞肺癌患者作为研究对象,依据随机数字表法分为观察组和对照组,各34例。对照组予以常规化疗(培美曲塞联合卡铂),观察组予以免疫检查点抑制剂联合抗血管生成药物治疗(卡瑞利珠单抗联合贝伐珠单抗注射液),1个治疗周期为21 d,至少治疗2个周期。随访18个月,比较两组治疗前后血清血管内皮生长因子(VEGF)水平、T淋巴细胞亚群水平(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、生活质量总体改善率、治疗效果及预后、不良反应发生情况。结果治疗后,观察组血清VEGF水平为(114.02±13.44)ng/L,低于对照组[(153.97±17.85)ng/L],差异有统计学意义(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前升高,CD8^(+)较治疗前降低,且观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平分别为(68.82±8.64)%、(35.35±8.97)%、2.49±0.85,均高于对照组[(64.32±8.02)%、(30.69±7.73)%、2.05±0.83],观察组CD8^(+)为(21.61±3.52)%,低于对照组[(25.01±6.53)%],差异均有统计学意义(P<0.05)。观察组治疗后生活质量总体改善率为61.76%,高于对照组的35.29%,差异均有统计学意义(P<0.05)。观察组的客观缓解率(ORR)、疾病控制率(DCR)为44.125%、85.29%,均高于对照组(20.59%、61.76%),中位无进展生存期(PFS)和中位总生存期(OS)6.64、13.89个月,均长于对照组(5.13、10.74个月),差异均有统计学意义(P<0.05)。两组均无不良反应相关死亡发生,在Ⅲ~Ⅳ级的血液性毒性、胃肠反应、肝功能异常、肾功能异常、乏力、皮疹上比较差异无统计学意义(P>0.05)。结论免疫检查点抑制剂联合抗血管生成药物治疗非小细胞肺癌的疗效明确,安全性较高,有利于免疫功能的恢复,提高生活质量,值得进一步研究应用。 展开更多
关键词 非小细胞肺癌 免疫检查点抑制剂 抗血管生成药物 疗效 安全性
下载PDF
上一页 1 2 25 下一页 到第
使用帮助 返回顶部